Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized Phase 1 placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and food effect of BMB-105 in healthy volunteers

Trial Profile

A randomized Phase 1 placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and food effect of BMB-105 in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 5-HT2C serotonin receptor agonists (Primary)
  • Indications Prader-Willi syndrome
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 06 Jan 2026 According to Bright Minds Biosciences media release, the company intends to use the net proceeds from the Offering of aggregate gross proceeds of USD100 million to fund initiation of phase 1 clinical drug trials for BMB-105.
  • 09 Dec 2025 New trial record
  • 06 Nov 2025 According to Bright Minds Biosciences media release, the company announced that the initiation of its Prader-Willi Syndrome (PWS) program. As part of the development program, Bright Minds will commence this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top